Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study

• Published in: IJID regions Vol. 15; p. 100611
• Main Authors: Thuluva, Subhash, Matur, Ramesh V, Gunneri, SubbaReddy, Mogulla, Rammohanreddy, Dhar, Chirag, Yerroju, Vijay, Balne, Nagaganesh, Chakravarthy, Bheemisetty S, Narang, Manish, Mahantshetti, Niranjana S, Pandey, Anil Kumar
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2025; Elsevier
• Subjects: Adverse events (AEs); Immune non-interference; Infectious Disease; Measles vaccine; National Immunization Program; Original Report; Typhoid conjugate vaccine (TCV); Adverse events (AEs); Measles vaccine; Immune non-interference; Typhoid conjugate vaccine (TCV); National Immunization Program
• ISSN: 2772-7076; 2772-7076
• DOI: 10.1016/j.ijregi.2025.100611

•Typhoid conjugate vaccines induce long-lasting T-cell responses, superior to Vi polysaccharide vaccines.•TYPHIBEV is World Health Organization–prequalified after phase I-III trials and now in routine use.•No safety signals when TYPHIBEV is co-administered with measles rubella in this phase IV trial...